Intercell AG announces Q4 and preliminary full year 2012 financial results and business update

Today, Intercell AG (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2012 and provided a business update.

Highlights

Further increase in product sales and reduction of net loss in 2012
Pediatric approval of Intercell’s Japanese Encephalitis vaccine in Europe
Merger between Intercell AG and Vivalis SA to create Valneva SE progressing well

For details please see the full Q4 report here.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.

Intercell AG announces Q4 and preliminary full year 2012 financial results and business update

Valneva announces the success of its private placement wraising approximately €60 million

Vetmeduni Vienna: Tödlich für Mensch und Tier: Studie liefert neues Wissen zur Verbreitung des Bornavirus

FFG FORUM 2024: „20 Jahre Zukunft: Perspektiven für den Innovationsstandort Österreich“